Investors

The event featured presentations from RedHill's management team who provided an overview of the Company's U.S. commercial strategy for launching Talicia^® and Aemcolo^®. RedHill’s expects to launch Aemcolo^® in Q4/19 and Talicia^® in Q1/20 with its expanding dedicated sales force. 

For further information please contact: investors@redhillbio.com

An abstract discussing the study’s top-line results, ‘A Phase III Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study To Assess The Efficacy And Safety Of Add-On Fixed-Dose Anti-Mycobacterial Therapy (RHB-104) In Moderately To Severely Active Crohn's Disease (MAP US)’ was presented as a late-breaking abstract today at the United European Gastroenterology Week (UEG Week 2018) by Dr. David Y. Graham, M.D., Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the MAP US study.